Bayer to buy Roche
This article was originally published in The Rose Sheet
Executive Summary
Bayer's proposed acquisition of Roche Consumer Health will create third largest OTC marketer worldwide, boosting Bayer HealthCare from its sixth-place spot to a position trailing only Johnson & Johnson and GlaxoSmithKline. Bayer/Roche combination is expected to have annual worldwide sales of $2.99 bil. Bayer's commitment to grow its consumer health business is reflected in the $2.96 bil. price tag it agreed to pay for Roche, representing twice the unit's annual sales. Under the deal, Bayer will acquire Roche's 50% share of the joint marketing venture for Aleve, which the firms have shared, as well as a number of other analgesic, dermatological, gastrointestinal and nutritional brands that will complement its own portfolio. Roche's leading consumer brands include Supradyn multivitamins, topical ointment Bepanthen, antacid Rennie and vitamin C supplement Redoxon. Company also manufactures Parsol UV filters...
You may also be interested in...
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.
Investors Go Berserk For Viking, Putting It Top Of Q1 Winners
The top 10 biggest share price winners and losers in Q1 from Evaluate show the investor frenzy for obesity drugs continues, while companies with governance doubts see shareholders retreat.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.